PT-141 (Bremelanotide) Reconstitution and Dosing Math: mg, mL, and Units Explained

What Is PT-141 and Why Does the Math Matter?

PT-141, the generic name for Bremelanotide, is a cyclic heptapeptide melanocortin receptor agonist that acts centrally on MC3R and MC4R receptors in the brain to increase sexual desire. The FDA approved the autoinjector formulation (Vyleesi, AMAG Pharmaceuticals) in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women at a dose of 1.75 mg subcutaneously [1]. Compounded versions are frequently dispensed as lyophilized powder vials that patients reconstitute themselves, which is where dosing errors occur.

Getting the math wrong by even a small margin changes the active dose delivered. Too little produces no clinical effect; too much raises the risk of nausea, flushing, and transient blood pressure changes that were the most common adverse events in Phase 3 trials [2]. The arithmetic is straightforward once the three variables, vial peptide mass, diluent volume added, and syringe unit markings, are understood as a system.

How the FDA-Approved Dose Was Established

The Phase 3 trial program (RECONNECT studies) enrolled 1,267 premenopausal women with HSDD across two double-blind, placebo-controlled trials. Bremelanotide 1.75 mg produced a statistically significant improvement in the Female Sexual Function Index desire domain score versus placebo (P<0.001), with a mean increase of 0.4 points on the Desire domain at 24 weeks [2]. That 1.75 mg dose informs the ceiling for compounded use; many prescribers start patients at 1.25 mg to reduce nausea rates, which reached 40% at 1.75 mg in the RECONNECT data [2].

Melanocortin Receptor Pharmacology

Bremelanotide binds MC3R and MC4R with nanomolar affinity. MC4R agonism in the hypothalamus appears to be the primary driver of pro-sexual CNS signaling based on receptor-knockout rodent models [3]. This central mechanism distinguishes PT-141 from phosphodiesterase-5 inhibitors, which act peripherally on vascular smooth muscle. The FDA label notes no reliable effect on genital blood flow as a standalone mechanism, which means the dose-response relationship is primarily neurological rather than vascular [1].

Bacteriostatic Water: Why It Is the Right Diluent

Bacteriostatic water for injection (BWFI) contains 0.9% benzyl alcohol as a preservative, which inhibits microbial growth and extends multi-dose vial stability to approximately 28 days after reconstitution when refrigerated [4]. Sterile water for injection (SWFI) contains no preservative; once a SWFI-reconstituted vial is punctured, it must be used within four hours under USP Chapter 797 compounding standards [5].

USP 797 Compounding Standards

USP General Chapter 797 (Pharmaceutical Compounding of Sterile Preparations) classifies reconstituted peptide vials as Category 1 or Category 2 compounded sterile preparations depending on sterility testing and beyond-use dating assigned by the compounding pharmacy [5]. When a patient reconstitutes a vial at home using BWFI supplied by the pharmacy, USP 797 guidance supports a beyond-use date of no more than 28 days refrigerated, provided the vial is punctured under clean conditions [5]. Freezing a reconstituted peptide vial is not recommended because repeated freeze-thaw cycles degrade the benzyl alcohol preservative system and may cause peptide aggregation [6].

Benzyl Alcohol Concentration Matters

Standard BWFI contains 0.9% benzyl alcohol (9 mg/mL). At the volumes used in PT-141 reconstitution (1 to 2 mL total), the benzyl alcohol load per injection is well below the 5 mg/kg/day threshold associated with toxicity in neonates [4]. Adult patients receiving 1.25 to 1.75 mg PT-141 doses drawn from a BWFI-reconstituted vial receive approximately 0.9 to 1.8 mg benzyl alcohol per injection, which poses no clinically meaningful risk for healthy adults [4].

Step-by-Step Reconstitution Protocol

Proper technique reduces contamination risk and ensures the peptide dissolves completely without degradation from mechanical agitation.

Materials Checklist

• 10 mg lyophilized PT-141 vial (compounded, sealed with rubber stopper)
• 2 mL bacteriostatic water for injection vial
• One 3 mL draw-up syringe with 21-gauge needle (for transferring BWFI)
• One or more 1 mL insulin syringes (29- or 31-gauge, 100 units/mL) for dosing
• Alcohol swabs
• Clean flat surface

Reconstitution Steps

1. Swab the rubber stopper of both vials with a fresh alcohol swab. Allow 30 seconds to dry.
2. Draw 2 mL of BWFI into the 3 mL syringe. Air-inject slowly against the glass wall of the PT-141 vial rather than directly onto the powder cake. Direct jetting denatures peptide bonds and causes foaming [6].
3. Gently swirl the vial in a circular motion for 15 to 30 seconds. Do not shake or vortex. The lyophilized cake should dissolve completely into a clear, colorless solution. Discard the vial if the solution appears cloudy or particulate.
4. Label the vial with the date, concentration (5 mg/mL), and your initials. Refrigerate immediately at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) [6].

The FDA label for Vyleesi specifies that the approved autoinjector formulation be stored at room temperature and used as a single dose [1]. Compounded multi-dose vials follow the longer refrigerated timeline permitted by BWFI, but the 28-day window is a ceiling, not a guarantee of stability in all conditions [5].

The Core Dosing Math: mg, mL, and Units

This is where most patient errors occur. Three numbers govern every draw: peptide mass in the vial (mg), diluent volume added (mL), and the unit markings on the insulin syringe.

Concentration Formula

Concentration (mg/mL) = Peptide mass (mg) / Diluent volume added (mL)

For a 10 mg vial with 2 mL BWFI added:

10 mg / 2 mL = 5 mg/mL

For a 10 mg vial with 1 mL BWFI added:

10 mg / 1 mL = 10 mg/mL

The 5 mg/mL dilution is preferred for starting doses because smaller dose increments can be drawn more accurately with a standard insulin syringe [7].

Converting mg Dose to Syringe Units

A standard U-100 insulin syringe holds 1 mL and is marked in 100 units. Each unit therefore equals 0.01 mL. At 5 mg/mL concentration, each unit drawn delivers:

5 mg/mL × 0.01 mL/unit = 0.05 mg per unit

Dose (units) = Desired dose (mg) / 0.05 mg per unit

| Desired dose | Units to draw (5 mg/mL) | Volume drawn | |---|---|---| | 0.5 mg | 10 units | 0.10 mL | | 1.0 mg | 20 units | 0.20 mL | | 1.25 mg | 25 units | 0.25 mL | | 1.5 mg | 30 units | 0.30 mL | | 1.75 mg | 35 units | 0.35 mL | | 2.0 mg | 40 units | 0.40 mL |

At 10 mg/mL concentration, each unit delivers 0.10 mg, so a 1.75 mg dose requires only 17.5 units (round to 18 units). The 10 mg/mL dilution compresses the scale and makes small errors proportionally larger. Most compounding pharmacies and prescribers default to 5 mg/mL for this reason [7].

Dose Range in Clinical Practice

The FDA-approved ceiling dose is 1.75 mg per 24-hour period for Vyleesi [1]. Compounded protocols often start at 1.25 mg to minimize nausea, titrating up to 1.75 mg after the first two or three uses if tolerability is acceptable. The RECONNECT trials showed nausea rates of 40% at 1.75 mg compared to 1% on placebo, with most events resolving within 12 hours [2]. A 1.25 mg starting dose is consistent with the prescribing principle of using the lowest effective dose for initial exposure, as described in the American Urological Association's position on off-label peptide therapies [8].

Insulin Syringe Selection and Injection Technique

Choosing the Right Syringe

U-100 insulin syringes (100 units per mL) are the standard tool for drawing compounded peptide doses. They are available in 0.3 mL (30-unit), 0.5 mL (50-unit), and 1.0 mL (100-unit) barrel sizes. For the dose range of 1.25 to 1.75 mg at 5 mg/mL, the 0.5 mL (50-unit) syringe offers the best graduation visibility because the 25- to 35-unit range sits near midscale rather than at the very bottom of a 1 mL barrel [7].

Needle gauge affects injection comfort. A 29-gauge, 0.5-inch needle is suitable for most abdominal subcutaneous tissue. For patients with very little subcutaneous fat, a 31-gauge, 3/8-inch needle minimizes discomfort and reduces the risk of inadvertent intramuscular injection [9].

Drawing the Dose

1. Remove the PT-141 vial from refrigeration. Allow 5 minutes to reach room temperature to reduce injection discomfort.
2. Swab the stopper with an alcohol swab. Allow 30 seconds to dry.
3. Draw back the syringe plunger to the target unit marking to load air equal to the intended draw volume. Inject that air into the vial to equalize pressure, which prevents vacuum buildup and makes drawing easier.
4. Invert the vial. Draw the solution to the target unit line. Remove the needle from the vial with the plunger at the correct marking.
5. Flick out any air bubble and advance the plunger to expel air. Recheck the unit marking.

Subcutaneous Injection Steps

Choose an injection site on the lower abdomen at least two inches from the navel, or the outer thigh. Pinch one to two inches of skin, insert the needle at a 45-degree angle, release the pinch, and inject the full dose slowly over five seconds. Withdraw the needle at the same angle. Apply light pressure with a dry gauze pad; do not rub [9]. Rotate injection sites to prevent lipodystrophy at repeated puncture points.

Stability, Storage, and Beyond-Use Dating

Peptide stability after reconstitution depends on temperature, light exposure, pH, and the preservative system [6]. Published stability data for Bremelanotide specifically are limited to the Vyleesi autoinjector formulation; compounded lyophilized vials rely on general peptide stability principles and USP 797 guidance [5].

Refrigerated Storage (Recommended)

Reconstituted vials kept at 2 to 8 degrees Celsius and protected from light retain peptide integrity for up to 28 days when BWFI is used as the diluent [5]. A 2022 review in the AAPS Journal examining melanocortin peptide stability found that cyclic peptides including ring-constrained analogs showed less degradation than linear peptides at equivalent storage temperatures, supporting the 28-day window for compounded Bremelanotide formulations [6].

Signs of Degradation

Discard the vial without use if you observe:

• Cloudiness, turbidity, or precipitate in the solution
• Yellow or brown discoloration (clear and colorless is expected)
• Visible particles that do not dissolve with gentle swirling
• Any odor (the solution should be essentially odorless)

The FDA's guidance on drug product quality attributes for sterile compounded preparations lists particulate matter and color change as primary rejection criteria [10].

Freeze-Thaw Prohibition

Do not freeze a reconstituted vial. Freeze-thaw cycles cause peptide aggregation and BWFI preservative degradation. Lyophilized (unreconstituted) vials, however, may be stored frozen at -20 degrees Celsius for longer-term preservation, consistent with general lyophilized peptide storage recommendations [6]. Reconstitute only when ready to begin a dosing cycle.

Adverse Effects Tied to Dosing Errors

Getting the dose right is not only about efficacy. Overdose by miscalculation raises the likelihood of adverse events documented in clinical trials and post-marketing surveillance.

Nausea and Flushing

Nausea is the most common adverse event with Bremelanotide, occurring in 40% of women at the 1.75 mg dose in RECONNECT versus 1% on placebo [2]. Flushing occurred in 20% at 1.75 mg [2]. Both effects are dose-dependent. A miscalculation that delivers 2.5 mg instead of 1.25 mg effectively doubles melanocortin receptor stimulation and may produce severe nausea within 45 minutes of injection.

Transient Blood Pressure Changes

The FDA label for Vyleesi includes a warning about transient decreases in blood pressure and increases in heart rate. In Phase 2 dose-ranging studies, mean systolic blood pressure decreased by approximately 6 mmHg and diastolic by approximately 4 mmHg at the 1.75 mg dose, returning to baseline within 12 hours [1]. Patients with baseline hypotension or those taking antihypertensives should use the lowest effective dose [1].

Hyperpigmentation

Focal hyperpigmentation of the face, gums, and breasts has been reported with repeated dosing in the RECONNECT long-term safety extension, occurring in approximately 1% of patients [2]. This effect is a class effect of MC1R agonism by melanocortin peptides and is more likely with supratherapeutic dosing or higher-than-recommended frequency of use [3].

Common Calculation Scenarios

Scenario 1: 10 mg Vial, 2 mL BWFI, 1.25 mg Dose

Concentration: 10 ÷ 2 = 5 mg/mL. Each unit on a 100-unit syringe = 0.05 mg. Units needed: 1.25 ÷ 0.05 = 25 units.

Scenario 2: 10 mg Vial, 1 mL BWFI, 1.75 mg Dose

Concentration: 10 ÷ 1 = 10 mg/mL. Each unit = 0.10 mg. Units needed: 1.75 ÷ 0.10 = 17.5 units (draw to 18 units; acceptable rounding for subcutaneous administration) [7].

Scenario 3: 5 mg Vial, 1 mL BWFI, 1.25 mg Dose

Concentration: 5 ÷ 1 = 5 mg/mL. Each unit = 0.05 mg. Units needed: 1.25 ÷ 0.05 = 25 units. Same draw as Scenario 1. The vial contains fewer total doses: 5 mg ÷ 1.25 mg per dose = 4 doses.

Scenario 4: 10 mg Vial, 2 mL BWFI, 0.5 mg Test Dose

Concentration: 5 mg/mL. Units needed: 0.5 ÷ 0.05 = 10 units. A 0.5 mg micro-test dose is used by some prescribers to assess tolerability before moving to full therapeutic dosing. There is no FDA-validated protocol for this practice, but it reflects standard dose-escalation pharmacology [8].

Prescriber Considerations and Off-Label Use in Men

The FDA approval for Bremelanotide applies only to HSDD in premenopausal women [1]. Use in men for erectile dysfunction or low libido is off-label. A Phase 2 study by Diamond et al. (N=293) demonstrated that Bremelanotide 7.5 mg intranasally produced significant improvements in erectile function versus placebo (P<0.01), though the intranasal route was abandoned due to transient blood pressure effects [11]. Subcutaneous compounded PT-141 is used off-label by men at doses ranging from 1.0 to 2.0 mg. These uses are not FDA-approved, and prescribers operating within telehealth platforms must document medical necessity, informed consent covering off-label status, and ongoing monitoring consistent with the principles in the AUA's clinical practice guidance on novel sexual medicine therapeutics [8].

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes that central melanocortin agonism represents a validated pharmacological target for desire-related dysfunction and supports individualized dosing to minimize adverse effects [12]. The same individualization principle applies when prescribers use compounded formulations, where patient-specific concentration choices affect the granularity of dose titration available.

A prescriber writing a compounding order should specify vial peptide mass, reconstitution volume, resulting concentration, dose in milligrams (not units), frequency of use, and route, so the patient's calculations are fully specified and error risk is minimized [5].